UK patients to be barred from first new lupus drug in 50 years Pharma Times In addition, some patients with severe disease currently receive rituximab off-label. Although it is not licensed for this use, the Committee would have liked to see data comparing the cost of Benlysta and rituximab, as it is used in clinical practice. |
